ArticleTrends in analytical chemistry : TRAC2010
Biomarker discovery and clinical proteomics.
Article in Trends in analytical chemistry : TRAC, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Quantitative Proteomics and CRISPR/Cas9 Editing Reveal UPR-Mediated Control of Immunoglobulin Homeostasis in Hybridomas.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Circulating enolase 1 as a diagnostic biomarker for early-stage breast cancer.NPJ precision oncology · 2025Article
- Exploring Metabolic and Immunological Biomarkers for Oral Squamous Cell Carcinoma: Potential Targets for Precision Therapy.Biology · 2025Review
- Ultrasensitive, Multiplexed Buoyant Sensor for Monitoring Cytokines in Biofluids.Nano letters · 2023Article
- Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases.Pharmaceutics · 2023Review
- Label-Free Quantification from Direct Infusion Shotgun Proteome Analysis (DISPA-LFQ) with CsoDIAq Software.Analytical chemistry · 2023Article
- Effects of filtration and alpha-amylase depletion on salivary biochemical composition measurements.PloS one · 2023Article
- Adjunctive Techniques and Diagnostic Aids in the Early Detection of Oral Premalignant Disorders and Cancer: An Update for the General Dental Practitioners.Journal of pharmacy & bioallied sciences · 2022Review
- Current Scientific Research Trends on Salivary Biomarkers: A Bibliometric Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- A novel strategy for identifying biomarker in serum of patient with COVID-19 using immune complex.Signal transduction and targeted therapy · 2022Article
- Label-Free Physical Techniques and Methodologies for Proteins Detection in Microfluidic Biosensor Structures.Biomedicines · 2022Review
- Childhood Allergy Disease, Early Diagnosis, and the Potential of Salivary Protein Biomarkers.Mediators of inflammation · 2021Review
- Differential expression of peptides serves as an indicator of IgA nephropathy in pediatric patients.Experimental and therapeutic medicine · 2020Article
- Salivary inflammatory proteins in patients with oral potentially malignant disorders.Journal of clinical and experimental dentistry · 2019Review
- iTRAQ Quantitative Proteomic Analysis of Vitreous from Patients with Retinal Detachment.International journal of molecular sciences · 2018Article
- Advancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid Biopsy.Diagnostics (Basel, Switzerland) · 2017Review
- Oral Biofluid Biomarker Research: Current Status and Emerging Frontiers.Diagnostics (Basel, Switzerland) · 2016Review
- [Screening and identification of apolipoprotein A-I as a potential marker for hepatoblastoma in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis.Journal of proteome research · 2016Review
- Screening and identification of apolipoprotein A-I as a potential hepatoblastoma biomarker in children, excluding inflammatory factors.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis).Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity and specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue.Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.